Category: News

Southern Research at 75: Engineers assist ‘Return to Flight’ Shuttle missions

Just three months after Charles J. Camarda flew on NASA’s pivotal STS-114 Space Shuttle mission in 2005, the astronaut paid a visit to Southern Research — and he brought souvenirs.

Shuttle astronaut Charles Camarda visited Southern Research in 2005. (Image: NASA)
Shuttle astronaut Charles Camarda visited Southern Research in 2005. (Image: NASA)

STS-114 was one of the most important Shuttle missions for a simple reason: It represented the “Return to Flight” for the space agency after the tragic loss of Columbia two years earlier.

Camarda served as a mission specialist on Discovery, which covered 5,796,419 miles and circled the Earth 219 times at speeds reaching nearly 17,700 miles per hour. During the mission, the Shuttle docked with the International Space Station, and the crew tested new flight-safety procedures and damage inspection and repair techniques.

Camarda visited Birmingham on Nov. 10, 2005, to talk with Southern Research engineering teams that had helped NASA understand how the Columbia accident unfolded and worked to devise new safeguards to prevent a repeat.

To show the Discovery crew’s gratitude, Camarda presented the engineers with a Southern Research banner that had been aboard the Shuttle during the 14-day mission. He also gave them a composite containing a U.S. flag that also had flown on STS-114.

SR 75th_Logo_Horz_RGBThe visit of Camarda, an aerospace engineer who had supervised NASA test facilities, represented a special moment for the Southern Research team.

“We’ve had the opportunity to work closely with Charlie on a series of efforts prior to his selection to fly on STS-114,” John Koenig, director of materials research, said at the time. “We share a heritage in materials engineering with Charlie, making this flight even more special in that ‘one of us’ was on board.”

ACCIDENT INVESTIGATION

Southern Research's John Koenig inspects a fuel nozzle damaged on an early Shuttle mission.
A Southern Research engineering team led by John Koenig identified a serious Space Shuttle fuel nozzle problem.

Soon after the Columbia accident on Feb. 1, 2003, Koenig and the Southern Research team became heavily involved in a wide-ranging quest for answers to what had happened to the Shuttle.

NASA engaged Southern Research in multiple roles in the inquiry. The team looked into aspects of the obiter wing failure, triggered when super-heated gases entered through damaged tiles on the leading edge.

Engineers modeled the impact of the foam debris that struck the left wing’s leading edge 82 seconds after Columbia’s lift-off, causing the damage.

Impact tests were conducted on materials that could come off the launch system during lift-off: ice, insulating foam, composite materials, graphite from the booster separation system.

Southern Research engineers prepared specimens, conducted pre- and post-nondestructive evaluation, and studied damage modes. They also developed new testing techniques that avoided the release of debris from the booster separation motors.

In addition, the team evaluated whether the age of the carbon-carbon composites on the leading edge enhanced the probability of failure after repeated exposures to temperatures reaching 3,000 degrees.

The engineers also worked with teams that studied potential in-flight repairs to the Shuttle’s leading edge, such as patches, plugs, overwrap, and fillers. Astronaut Scott Parazynski acted as an adviser to the Southern Research team on this program.

‘SILVER SNOOPY’

After Discovery returned to Edwards Air Force Base in California to end STS-114 on Aug. 9, 2005, NASA didn’t mount another mission for almost another year. STS-121, launched on July 4, 2006, was considered the second “Return to Flight” mission for the Shuttle program.

On both of these missions, NASA had what it called “eyes in the sky” to record the lift-off and its climb toward orbit. High-flying WB-57 aircraft carried an innovative nose-mounted video system that allowed NASA to monitor the flight for debris impacts.

Southern Research’s Airborne Imaging and Recording System is still in use.

On STS-121, Discovery again returned to the International Space Station, and the crew continued to test new equipment for the in-flight inspection and repair of the Shuttle’s thermal protection system.

After the mission, NASA decided that the Shuttle was prepared to resume its scheduled flights.

That year, Koenig received a Silver Snoopy Award, an honor given by NASA astronauts for contributions that improve the success and safety of space flight.

 

This is Part Seven of a series looking at the history of Southern Research.

 

 

NIH director thanks Southern Research for ‘treatments, cures and real hope’

In a message to mark Southern Research’s 75th anniversary, Dr. Francis S. Collins, director of the National Institutes of Health, praised the organization’s scientists for making significant advances against cancer and other diseases.

“Since 1941, Southern Research has made advances that have helped people all across this country – in fact, all around the globe,” Collins said in a video shared with the Birmingham-based non-profit.

In particular, the leader of NIH, the nation’s chief medical research agency, noted the achievements of Southern Research’s long-standing cancer research program. The organization’s scientists played key roles in developing effective chemotherapy methods and in the discovery and development of numerous FDA-approved oncology treatments.

“Of the 200 or so drugs currently used to treat cancer, seven were discovered at Southern Research,” Collins said. “In fact, two of them – fludarabine and clofarabine – are even on the World Health Organization’s list of essential medicines.”

In addition, Southern Research has provided vital research tools and models that allowed other scientists to advance the development of cancer therapeutics, he said.

TARGETING DISEASES

While efforts to discover new oncology drugs continues at Southern Research, Collins noted that its scientists are also working on potential therapeutics for Alzheimer’s, Parkinson’s, diabetes, Lou Gehrig’s disease, and tuberculosis, among others.

At the same time, Southern Research is helping researchers around the world test new disease-fighting strategies. “The area of HIV/AIDS research has been a real standout,” he said.

Collins singled out Southern Research’s work in the field of reproductive toxicology, which seeks to prevent birth defects, and on the Zika virus, which has suddenly emerged as a serious threat to public health around the world.

Collins also responded to a letter from Southern Research CEO and President Art Tipton, Ph.D., who thanked the NIH for providing the Birmingham non-profit with more than $500 million in funding over the past three decades.

“Mr. Tipton, I want to let you, along with all of Southern Research and its supporters, know that you are indeed welcome,” Collins said. “And on behalf of the NIH and the American taxpayer, I want to thank you, Southern Research, for a tremendous return on this investment – a return measured in treatments, cures and real hope for a better future for people all around the world.

Southern Research at 75: Labs spin out new fabrics and capabilities

From its earliest days, Southern Research scientists were engaged in textile projects such as devising new techniques for spinning yarn, developing novel polymers for synthetic fibers, and designing special purpose garments.

Their work yielded a number of advances: new wrinkle-shedding fabrics, improved materials for carpets, innovative methods for producing types of Nylon. Southern Research laboratories also developed a fabric for astronaut life rafts and a garment to protect steelworkers, among other things.

Southern Research textile technology
Southern Research fiber-spinning labs produced many advances.

Dr. Wilbur Lazier, the organization’s first director, established a Textile Research Group as one of his first moves after his hiring in 1944. The research emphasis reflected the critical importance of the textile industry to the South’s economy in those days.

Not surprisingly, much of Southern Research’s early work on textiles focused on cotton, which remained a major cash crop across the region.

The organization’s research on cotton focused on just about every aspect of how it could be processed – spinning, bleaching, dyeing, and finishing. In 1946, Textile Division head Dr. Robert J. Taylor used an experimental hot-air slasher to study the effects of sizing to improve yarn strength for Minneapolis-based Pillsbury Mills.

Programs were carried out for textile companies, chemical manufacturers, and government agencies.

The work resulted in the development of:

  • New treatments to produce wash-and-wear cotton fabrics
  • New lubricants and sizing formulations for processing cotton yarn
  • New ways to use synthetic rubber latexes to improve the performance of cotton garment fabrics and the resiliency of cotton-pile carpets
  • New flame-proofing treatments

SYNTHETIC FIBERS

SR 75th_Logo_Horz_RGBCotton wasn’t the only focus of Southern Research scientists.

Lab work on synthetics became extensive, centering on the preparation of polymers and the production of fibers, as well as the processing and finishing of synthetic yarns and fibers.

Scientists evaluated totally new types of polymers for fabrics and studied new ways to make fabrics from batches of existing polymers. Facilities were installed at Southern Research for spinning synthetic fibers using various methods.

In the 1960s, some of this textile technology work focused on polypropylene, today considered one of the most versatile of plastics, found in area rugs, exercise apparel and many other items.

As part of this work, Southern Research developed a super-tenacity polypropylene fiber that won accolades from Industrial Research magazine, which named it one of its 100 most significant new products of 1963.

Southern Research textile technology
An early look at Southern Research’s textile spinning lab.

Southern Research scientists also conducted innovative work in Nylon production. In the 1960s, they developed Nylon 1313 from crambe oil, an inedible seed oil, and produced several hundred pounds of it for evaluation under a U.S. Department of Agriculture program.

In the 1970’s, Southern Research’s unique fiber-spinning capabilities permitted its scientists to develop a method to spin heat-sensitive Nylon 4 on standard melt-spinning equipment, an unmatched technical achievement.

Over the years, Southern Research developed several specialty products from its fiber work. These included:

  • Disposable garments for protection against noxious materials
  • A garment to shield workers in steel mills from molten metal splash
  • A fabric for life rafts for astronauts

This expertise in fiber-spinning and polymers would set the stage for Southern Research’s pioneering work in controlled-release technology and new drug delivery systems. The organization’s fiber-spinning work led to the development of the first synthetic, bio-absorbable surgical suture, introduced in the early 1970s.

 

This is Part Six of a series looking at the history of Southern Research.

Southern Research at 75: Helping Apollo spacecraft beat fiery re-entry

When the Apollo 11 flight crew returned from the historic Moon expedition on July 24, 1969, their command module pierced the Earth’s atmosphere traveling at 36,237 feet per second and became engulfed in a fireball burning at 5,000 degrees Fahrenheit.

NASA Apollo 11
This NASA rendering depicts the Apollo 11 capsule during re-entry. The capsule’s heat shield, developed with input from Southern Research, protected the astronauts from the incredible heat.

The capsule’s heat shield – developed with input from Southern Research – protected the astronauts, with a special epoxy resin in the shield’s honeycomb backing structure dissipating the intense heat while vaporizing in the hellish environment.

Long before the Apollo 11 crew splashed down in the Pacific, Southern Research’s expertise in high-temperature testing provided NASA with important information about the materials being considered for the spacecraft’s thermal protection system.

Under contracts with NASA’s Langley Research Center in Virginia during the 1960s, Southern Research engineers working in test facilities exposed specimens of various classes of materials to the harsh conditions of re-entry, including temperatures nearly three times the melting point of steel.

In rigorous evaluations under extreme conditions, Southern Research engineers recorded more than a dozen different thermal and mechanical properties of the heat shield materials. Afterwards, mathematical models were developed to predict actual performance during re-entry.

AN UNUSUAL ‘BALL OF STRING’

Before the Apollo program even got off the ground, Birmingham-based Southern Research had performed high-temperature work for government sponsors and aerospace companies, beginning in the 1950s. Under the guidance of Coultas “Colt” Pears, its high-temp testing lab gained an international reputation for work on advanced materials like carbon-carbon composites.

Pears recalled that he first saw the exotic composite material early on, when “a fellow walked in with a ball of string and asked me to dip it in sugar water and heat it to 5000°F.”

SR 75th_Logo_Horz_RGB“It was 15 years before the material became a heat shield or nose tip,” he said.

In addition to work on the space program, Southern Research engineers conducted important materials evaluation work on key U.S. missile systems. In 1967, the U.S. Navy recognized the organization’s role in the development of the Polaris missile system with a special award.

Pears’ ambition at Southern Research was to create a world-class high-temperature materials characterization laboratory. His lab developed a facility that could make accurate measurements of loads on brittle high-temperature metals. Another innovation involved new optical strain measurement techniques.

The first known measurements of tensile properties at 6,000 degrees Fahrenheit took place at Southern Research, and extreme-temperature testing and analysis became a core competency of the organization.

ASSISTING APOLLO SPACECRAFT

Apollo 11
Apollo 11 lifted off on its historic mission to the Moon on July 16, 1969. (Image: NASA)

Southern Research’s contributions to the Apollo program weren’t limited to materials evaluation.

Engineers were involved in several instrument development programs. One of those focused on the design of a radiometer that was paired with a telescope to take temperature readings on the Moon’s surface. The instrument was part of a critical NASA program to select landing sites for Apollo missions to the lunar surface.

In another Apollo project, Southern Research engineers used graphite sensing elements to build several calorimeters to measure heating rates on various portions of the Saturn booster exit.

Other groups at Southern Research also got involved in work on the Apollo spacecraft program.

Around the time of the Apollo 1 fire in 1967, the organization established onsite laboratory operations at Kennedy Space Center to support contractors involved in launches of the giant Saturn rockets. The 25 staffers evaluated spacecraft materials and attempted to pinpoint the causes of malfunctions in connections.

At that time, chemist Ruby James was Southern Research’s specialist in gas chromatography, a means to separate the different components of a mixture by forcing gas through a column.

The program at Kennedy Space Center ran for two years.

After the last Apollo mission, Southern Research remained active in the nation’s space program, making important contributions to the Space Shuttle and working on projects including the Voyager probe and the James Webb Space Telescope.

Today, Southern Research engineers are involved in the Space Launch System, a NASA project that aims to put man on Mars.

 

This is Part Five of a series looking at the history of Southern Research.

 

National Cancer Institute extends toxicology contract with Southern Research

NCI extends long-term toxicology contract with Southern Research.
NCI extends long-term contract with Southern Research for preclinical toxicology screening of cancer drugs.

Southern Research has been awarded a five-year IDIQ contract with a potential value of $19 million from the National Cancer Institute (NCI) to study the preclinical toxicology of new drugs under development for the treatment of cancer — contract number HHSN261201600018I.

The contract is one of three ongoing contracts between Southern Research and the NCI, and has been in place continuously since 1979. This is the latest in a series of contract extensions for the organization.

The two additional ongoing contracts between Southern Research and the NCI are for research on the pharmacology of potential new cancer drugs, and for evaluation of drugs intended for the prevention of cancer.

“Our ultimate goal with this contract is to help the NCI develop an understanding of how different drug candidates interact with and affect living systems,” said Charles Hébert, Ph.D., senior program leader and principal investigator on the project for Southern Research. “The collection of this information is necessary so the FDA can determine whether a particular drug candidate is safe for clinical trial testing in humans.”

Toxicology testing is an integral part of the drug development process. In order to determine the safety of a new drug candidate, researchers must first conduct dose range-finding studies to establish the maximum tolerated dose, and to aid in the selection of dose levels for use in further testing.

Once the appropriate dose range has been established for the selected species, larger and more detailed definitive studies are conducted. Those definitive studies differs from dose range-finding studies in that they require deeper and more thorough analysis of the ways a particular drug may affect animals, and by extension, humans. Ultimately, the definitive studies provide key information that is used by the FDA to determine the recommended dose options for any drug candidate approved for clinical trial.

“Southern Research has been at the pioneering forefront of cancer research for more than 70 years, and we are particularly proud of our work with the National Cancer Institute,” said Art Tipton, Ph.D., president and CEO of Southern Research. “We have invested heavily to develop unique capabilities and institutional knowledge in this field, and work diligently to stay on the forefront of the field enabling us to improve people’s lives by finding cures to some very challenging diseases.”

Southern Research drug clofarabine links leukemia patient, scientist

Frances Grace Hirs and Jack Secrist have never met, but their paths have crossed.

Frances Grace Hirs
While at Children’s Hospital, Frances Grace Hirs was visited by Alabama football players AJ McCarron, right, and Austin Shepherd.

Frances Grace is a 17-year-old junior at Fairhope High School, a member of the National Honor Society who enjoys painting and recently started driving. She’s making plans for the future and may pursue a career in pediatric oncology.

“She is flourishing,” said her mother, Debbie. “She’s just amazing.”

Frances Grace is also a fighter. She has battled acute lymphoblastic leukemia (ALL) since she was 3 years old – and that’s the source of her connection to Secrist, the former head of Southern Research’s Drug Discovery division.

Secrist, Ph.D., is co-inventor of clofarabine, a therapy for children whose leukemia has returned after two types of treatment have failed. Frances Grace received clofarabine while being treated at Children’s Hospital of Alabama during the summer of 2013, following a second relapse.

Debbie Hirs believes the drug discovered by Southern Research helped save her daughter’s life by getting Frances Grace’s leukemia into remission so that a bone marrow transplant could be performed on Sept. 7, 2013.

“Thank goodness there are people out there doing that work,” said Mrs. Hirs, who visited Southern Research’s Birmingham offices with Frances Grace and husband Allen last month.

Southern Research Secrist
Clofarabine co-inventor Jack Secrist

Secrist retired from Southern Research after a 34-year career and now lives in Michigan. He said it’s actually rare for the inventor of a cancer drug to meet someone who has been treated with that drug. But he knows the life-changing impact that work in the drug discovery field can have.

He glimpsed it first-hand at the Food and Drug Administration hearing when approval was granted for clofarabine back in 2004. (Read a story about the discovery of clofarabine.)

“A father brought his son to the hearing and he took advantage of the public forum to relate the story of his son and how this drug has certainly saved his life,” Secrist recalled.

“He was holding the boy, who was perhaps five or six, in his arms as he spoke. It was a moving scene.”

TRANSPLANTING HOPE

Frances Grace was diagnosed with the deadly blood cancer in 2003, after severe back pain left her screaming in agony. Her parents decided to make the 260-mile trek to Children’s Hospital for treatment, and she was soon in remission.

But in 2009, when she was in the third grade, Frances Grace felt a pain in her side after ballet class. Doctors confirmed that the leukemia had returned. A second round of chemotherapy at Children’s returned positive results.

In April 2013, the disease came back. Frances Grace’s third bout with ALL was serious, because her chemotherapy options were growing limited. She needed a bone marrow transplant but couldn’t undergo the procedure unless she was in remission.

“The transplant was her last hope,” Mrs. Hirs said.

Frances Grace Hirs
Frances Grace Hirs met her bone marrow donor, Barry Schneider, at Children’s Hospital in August.

Frances Grace’s doctor recommended clofarabine, and the drug worked rapidly, making the transplant possible, Mrs. Hirs said. The teenager still faced a long, difficult recovery period, but she was able to return home shortly before Christmas 2013.

Last month, Frances Grace met her bone marrow donor, when Bryan Schneider of New Braunfels, Texas, traveled to Birmingham for a ceremony at Children’s Hospital.

The Hirs family visited Southern Research after learning clofarabine had been discovered there.

DISCOVERING CLOFARABINE

The work that led to clofarabine began around 1983, when Southern Research scientists were searching for new anticancer drugs based on nucleosides, the building blocks of DNA.

Secrist said the team saw promise in two potential drugs, but an evaluation revealed structural concerns with both. He and John Montgomery, Ph.D., a key member of Southern Research’s drug discovery team, formulated a plan. They set out to create new compounds that would disrupt DNA function in cancer cells in a similar way while lacking the structural issues that had raised concerns with the others. *

“We made this series of compounds, and the end result was clofarabine,” said Secrist said.

Frances Grace Hirs
The Hirs family: Debbie, Frances Grace, Allen.

Later, while clofarabine was in clinical development at M.D. Anderson Cancer Center in Houston, a chance development proved critical in the drug’s long journey toward FDA approval.

“A family had a child that had gone through the available drugs for his leukemia, and he was not responding,” Secrist said. “They asked to be able to try clofarabine, which was not yet available for trials, and their request was granted.

“The child responded immediately, and the family was truly grateful,” he added.

When clofarabine received FDA approval on Dec. 28, 2004, it was the first new drug to treat childhood cancers in a decade. The drug, marketed in the U.S. by Sanofi Genzyme, carries the brand name Clolar.

The Hirs family is deeply grateful for the medical research that has benefited Frances Grace. They organized a golf tournament in Baldwin County to raise money for Children’s and cancer research. The tournament, now in its 12th year, has raised $700,000, including $110,000 last year.

“People need to know that it takes money to do these things,” Allen Hirs said. “It just takes a lot of people and a lot of effort.”

 

*Both of the other compounds – fludarabine and cladribine — won FDA approval as treatments for leukemia. Fludarabine, first synthesized by Montgomery, was approved in 1991 as a therapy for chronic lymphocytic leukemia. It’s one of five cancer drugs invented or co-invented by Montgomery while at Southern Research.

Clofarabine co-inventor Jack Secrist talks about drug discovery

Drug discovery researchers like Jack Secrist are motivated by a strong desire to see their work save lives and make a profound difference.

Secrist, the former head of Drug Discovery at Southern Research, is co-inventor of clofarabine, a drug approved by the Federal Drug Administration in 2004 for acute lymphoblastic leukemia (ALL) in pediatric patients like Frances Grace Hirs.

Frances Grace was battling a third bout of ALL in 2013 when she was treated with clofarabine, which helped put her on the road to recovery. (Read a story about her treatment.)

clofarabine-poster“This is what we all aspire to as drug discovery researchers, moving life-saving compounds from conception to clinic,” Secrist said in 2005, shortly after clofarabine received FDA approval.

In a new interview, Secrist talks about how he and his Southern Research colleagues discovered clofarabine and how the drug moved along to the path to become the first treatment for childhood cancer approved by the FDA in more than a decade.

In this Q&A, Secrist also shares his views on how Southern Research, which has discovered seven FDA-approved drugs used in cancer treatment, has been able to consistently develop new therapies that address unmet medical needs.

Southern Research was visited recently by Frances Grace Hirs, who was treated with clofarabine after a second leukemia relapse. Her parents credit the drug with stabilizing her condition, making a bone marrow transplant possible. As a co-inventor of the drug, do you hear stories like this often?

Secrist: In my experience, at least as it pertains to chemists who are inventors of cancer drugs that end up being FDA approved, it is rare that you would meet someone who had benefited from the drug unless it happens to be a family member, friend, or acquaintance. The inventors are far removed from both the oncologists who select the drugs and the patients who take them.

Southern Research Secrist
Clofarbine co-inventor Jack Secrist

In this situation, I can relate two stories. I did meet a father and a daughter who had benefited from the drug in Birmingham, and they were focused on making sure that others who might benefit from the drug would be appropriately informed.

The other time that I saw patients who benefited from the drug was at the FDA hearing where the drug was approved. A father brought his son to the hearing and he took advantage of the public forum to relate the story of his son and how this drug has certainly saved his life. He was holding the boy, who was perhaps five or six, in his arms as he spoke. It was a moving scene.

How did the work that led to clofarabine get started?

Secrist: This question is somewhat more technical, but I will provide some information about how we moved toward the drug that became clofarabine. First, we were working in the nucleoside area, looking for drugs that would affect DNA function in cancer cells, which was at the time the best way to develop a new cancer drug. We chose to work on nucleosides since they are the building blocks of DNA, and we felt that finding something that would be recognized by the cancer cells, and perhaps have selectivity, was more likely in this area.

At the time, around 1983, we had funding from National Institutes of Health (NIH) in the form of what is called a program project grant to search for new drugs in this area, and to evaluate them in biological systems. There were two potential drugs that looked promising at the time that were nucleosides, and we had the detailed biological data to be aware of structural concerns with both drugs.

John Montgomery (an organic chemist and key member of the cancer research team) and I then formulated a plan to make a series of new compounds that would be similar enough that they might have activity, but would have structural changes that would overcome the concerns we saw with these two potential drugs. We made this series of compounds, and the end result was clofarabine.

By the way, both of the other compounds also became FDA approved: one of them is fludarabine and the other is cladribine. Interestingly, the three compounds, though very similar in structure, are used for different forms of leukemia.

Can you recount any significant developments or insights that occurred during your work on this project?

Secrist: The first insight that we developed, which really was just a confirmation of what we already felt, was that very small changes in the structure of a molecule can result in very large changes in biological and clinical activity. The utility of clofarabine, fludarabine and cladribine is a clear demonstration of that fact, and it can be seen in other areas, as well.

placeholder
Secrist

Another insight that was strengthened was that the more robust the biological (anticancer) data is on a compound, the more likely it is to become FDA approved. Compounds with some activity and selectivity, but not really strong data, most likely will not make it through to approval. Clofarabine had very strong data supporting its move into clinical trials.

It is also true, by the way, that there is not a connection between what human tumors a potential drug can cure in model systems and what tumors it may cure in humans. It would be wonderful if that was the case, but at least with the current models no such correlation exists. Again, we get back to the fact that robust activity and selectivity data across a wide range of tumor types is the best indicator.

When clofarabine received FDA approval in 2004, it was the first new pediatric leukemia to hit the market in more than a decade. How would you assess its significance?

Secrist: Thinking back to the clinical development of the drug, which started at M. D. Anderson Cancer Center in Texas, there was a critical chance happening. A family had a child who had gone through the available drugs for his leukemia, and he was not responding. They asked to be able to try clofarabine, which was not yet available for trials, and their request was granted. The child responded immediately, and the family was truly grateful.

That chance happening suggested the best path to approval, that is, through a focus on childhood leukemia, though there were of course adult trials as well. The drug clearly helped children, and the FDA was very interested in finding a new drug for childhood cancers, and they were very helpful and supportive.

When the ODAC (Oncology Drug Advisory Committee), a group of outside clinicians, voted for approval, the FDA was really pleased to have the first new drug to treat childhood cancers in more than a decade.

Southern Research has discovered seven drugs used in cancer treatment. What made the organization such a hotbed for the discovery of anticancer drugs?

Secrist: In considering why Southern Research was so successful in developing new cancer drugs, I believe that there are a number of reasons. First, we had extremely talented scientists who were dedicated to the development of new drugs that would be useful in the treatment of cancer. The Dream Team in that regard comprised Howard Skipper, John Montgomery, Frank Schabel, and Lee Bennett. They worked together for many years, and together with their staff, were a very effective team.

Southern Research cancer team
The Southern Research ‘Dream Team:’ from left, Frank Schabel, Lee Bennett, Howard Skipper, and John Montgomery.

Second, that team developed an efficient and effective approach to the development of potential new drugs. New compounds were evaluated rapidly, and those with potential were subjected to more detailed evaluations as soon as possible, and compounds that had no activity or weak activity were set aside to make way for new compounds. This iterative approach to drug discovery is still in use today, though the biological systems have evolved over the years.

Finally, in the early years the Dream Team had not only their own ideas on the type of compounds to pursue in the search for new cancer drugs, but also the input of the cancer research team at the NIH. Thus, Southern Research scientists had access to the latest information available to NIH, including areas of activity, clinical results, and evaluation model advances.

In the early years Institute scientists would go up to NIH to present results, and would of course hear presentations about the results of others. In later years we used scientific meetings and personal contacts to gain that information. The result was an ability on our part to look in more fertile fields for new cancer drugs.

 

Southern Research at 75: ‘Boss Kettering’ provides key early support

Charles Kettering, the genius engineer behind many of General Motors’ breakthrough innovations, racked up 186 patents and earned a reputation as a great inventor in his day.

Southern Research Skipper Kettering
Southern Research’s Howard Skipper, left, talks with famed inventor Charles Kettering, a strong supporter of Skipper’s cancer research.

He also became a high-profile supporter of Southern Research in its early days, thanks to a relationship with the new research organization’s chairman, Thomas Martin.

Though the dynamic founder of Southern Research and the inventor of the automobile starter motor had exchanged letters since 1934, they didn’t actually meet until both attended a nutrition conference in New York in 1945. Martin told Kettering about the work getting under way in Birmingham.

Intrigued, Kettering contributed advice, expertise and funding to help accelerate growth at Southern Research, particularly the cancer program headed by Howard Skipper, Ph.D.

“I do remember very well that a lot of the early money when I joined Skipper’s group came from Kettering, and it was pretty soon after that we also got money from the Alfred P. Sloan Foundation,” recalled John Montgomery, Ph.D., a key member of Southern Research cancer team from 1952 until 1990.

“Sloan was the money man at General Motors when Ket was the inventor, and they tossed some money in the pot, too. And so we had enough money to begin to do something,” Montgomery added.

In 1945, around the time that Southern Research was launching its first projects, Kettering joined his GM colleague to open the Sloan-Kettering Institute for Cancer Research (SKI) in New York. SKI’s director was Cornelius Rhoads, who had served with Skipper in the Army’s chemical warfare section during World War II.

SR 75th_Logo_Horz_RGBThese connections would drive growth in Skipper’s labs.

‘BOSS KET’ COMES TO TOWN

Kettering made frequent visits to check on Southern Research’s progress. The first came on Nov. 12, 1947, dedication day for the organization’s first new building – Laboratory No. 5.

At the time, Southern Research had about 50 scientists, working on early projects such as heat pump technology, extending food uses of peanuts, new paints from coal by-products, and chemical detectors for the Army. Kettering talked to the scientists, toured the facilities, and spoke that night at the Chairman’s Dinner.

Charles Kettering Southern Research
Charles Kettering speaks at Southern Research during his first visit in 1947.

“Set up your laboratories, equip them,” he told the researchers. “You cannot tell what is going to come out of them now, or 10 or 15 years hence. Your achievements will be different from what you now think, but they will be wonderful.”

He was keenly interested in Skipper’s cancer program, which was started the year before thanks to a $25,000 gift from Mobile businessman Ben May.

“One of my favorite memories is of Boss Kettering, as we called him, and his visits to our group,” Montgomery recalled in an oral history of Southern Research published in 1991. “He came to see us three or four times a year, to talk to the boys and see how things were getting along on cancer research.”

He did more than just offer encouragement to Southern Research’s scientists. He made possible the organization’s first permanent labs for biomedical research — the Kettering-Meyer Laboratory.

The Charles F. Kettering Foundation contributed $200,000, and Birmingham’s Robert Meyer Foundation donated $100,000 for the lab. Kettering attended the groundbreaking on June 26, 1953, and Sloan was on hand to turn the first shovel.

Significantly, Sloan agreed to provide substantial funding to advance the cancer work being done at Southern Research under partnership with SKI.

Just five years later, K-M Laboratory II opened on Southern Research’s campus, a project spurred by the cancer program’s rapid growth.

Kettering was among Southern Research’s many important early benefactors. Besides May and the Meyer family, these include Robert I. Ingalls, Harry Frueauff Jr., Daniel Construction Co. and the Daniel Foundation.

 

This is Part Four of a series looking at the history of Southern Research.

Southern Research at 75: Ben May’s gift launches a cancer program

Southern Research Howard Skipper
Dr. Howard Skipper led Southern Research’s cancer program to many advances in chemotherapy.

Mobile lumber magnate Ben May wanted Southern Research to do something special with his $25,000 gift in early 1946.

The non-profit research organization’s original charter spelled out a mission to support the growth of Southern industry, but May demanded that his donation focus on improving human welfare in the region.

May’s seed money launched Southern Research’s cancer program, which over several decades has contributed to significant advances in cancer treatment and drug discovery.

Southern Research’s work in the 1950s and 1960s defined the fundamentals of effective cancer chemotherapy at a time when there was widespread skepticism about the practice. Led by Dr. Howard Skipper, the team demonstrated the principles of combination chemotherapy to counter resistance to a single drug.

Skipper’s strategy was straightforward. He would harness all of Southern Research’s resources to develop “concepts, hypotheses, theories, rules, laws, principles, mathematical models,” anything that would speed progress in the battle against cancer.

“Trial and error is a slow business,” Skipper recalled later. “But we have helped in forming a number of hypotheses that have withstood the test of time and proved helpful in providing guidance to many of our clinical associates in this country and abroad.”

IMPORTANT BONDS

Early on, Southern Research’s cancer program developed close ties to the Sloan-Kettering Institute for Cancer Research in New York, whose director, Dr. Cornelius Rhoads, had worked with Skipper in the Army Chemical Warfare Section during World War II. The Sloan-Kettering connection acted as a springboard.

SR 75th_Logo_Horz_RGBIn the 1950s, major funding for Southern Research’s cancer work began flowing in from the National Cancer Institute, a relationship still intact today, and the American Cancer Society, among others. Many individuals followed May’s lead with significant gifts.

Skipper’s cancer research program quickly grew in prominence.

Southern Research’s budget for health-related research in 1950 totaled less than $73,000. Ten years later, the figure was $1.7 million, more than half the entire budget.

Medical research remains a key focus for the organization.

“WHAT HE STARTED HERE”

Ben May
Ben May

May’s involvement with Southern Research didn’t stop with that game-changing $25,000 gift. He joined its board of directors in 1951 and remained a trustee for more than two decades. He also sponsored several research projects and contributed to the capital fund.

May and Skipper remained close over the years, often exchanging letters.

On Feb. 18, 1972, May replied to a letter he had just received from Skipper.

“Dear Howard:

“Thanks a lot for your letter of February 16. I note that you feel that my seed money was not wasted at the time of the Southern Research decisions. If there was success, I figure it was due to your ability and fine work,” May wrote.

In early November that year, May and Dr. Martin Perlman of Mobile traveled to Birmingham to visit Skipper at Southern Research. May sent a letter of thanks to Skipper on Nov. 9. “It was a real pleasure to be with you again,” he wrote, “and I felt fortunate that I could make the trip and see you as I did.”

A few days later, May was dead.

Soon after, Skipper wrote Perlman:

“I loved Mr. May. You may know it. I know that he knew it. I shall always be grateful to you for bringing him to the SRI Dinner not long ago, and for allowing us to have lunch and visit with you just a week before his passing.

“I sensed that he was happy with what he started here and that he was proud, almost as a father would be proud, or what we have been able to do and are trying to do,” Skipper wrote. “This is what I wanted so much for him to feel, but one can never repay the sort of help and inspiration he gave so unselfishly.”

 

This is Part Three of a series looking at the history of Southern Research.

SJR13: A resolution honoring Southern Research’s 75th Anniversary

AL State Capitol_SJR13Southern Research was founded in 1941 with the purpose of advancing science and becoming an economic driver for the region. Today, 75 years later, Southern Research employs nearly 500 people across five states, working to help solve the world’s hardest problems.

In recognition of this historic anniversary, the Alabama Legislature passed a joint resolution recognizing our hard work and commemorating the contributions Southern Research has made to science and engineering on behalf of our numerous clients.

Related: Southern Research through the years, a timeline.

We would like to thank Senators Rodger Smitherman and Jabo Waggoner for carrying this resolution, and our other friends in the legislature for their support. Your recognition means a lot to us, and we look forward to continuing our work to make Alabama and the world a better place.

Read the entire transcript below, or visit Legiscan to access a PDF of the joint senate resolution.

 

Senate Joint Resolution 13 (SJR13)

By Senators Smitherman, Waggoner, Albritton, Allen, Beasley, Blackwell, Brewbaker, Bussman, Chambliss, Coleman-Madison, Dial, Dunn, Figures, Glover, Hightower, Holley, Holtzclaw, Livingston, Marsh, McClendon, Melson, Orr, Pittman, Reed, Ross, Sanders, Sanford, Scofield, Shelnutt, Singleton, Smith, Stutts, Ward, Whatley and Williams

First Read: 18-AUG-16

SJR13

ENROLLED, SJR13,
RECOGNIZING SOUTHERN RESEARCH ON THE OCCASION OF ITS 75TH ANNIVERSARY.

WHEREAS, it is with highest commendation that we recognize the invaluable contributions to the betterment of mankind made by the scientists and engineers of Southern Research since its founding in 1941; and

WHEREAS, Southern Research, headquartered in Birmingham, Alabama, has served as a driver of economic development for the State of Alabama since its inception in a number of highly technical fields of discipline; and

WHEREAS, whether it is drug discovery, drug development, engineering, energy, and environment, or medical devices, the men and women of Southern Research are making contributions every day to help make the world a better place in which to live; and

WHEREAS, this 501(c)(3) nonprofit research and development organization has discovered seven FDA-approved anticancer drugs, a record rivaling any nonprofit research organization in the world; and

WHEREAS, in addition to cancer, the scientists of Southern Research are actively pursuing new drug therapies in Alzheimer’s, Parkinson’s, Tuberculosis, Kidney Disease, and Diabetes, in addition to other areas, and are proud partners in the Alabama Drug Discovery Alliance; and

WHEREAS, the organization’s drug development division has a notable record of achievement in the fields of infectious diseases and vaccine development, to include work in HIV/AIDS and mosquito borne viruses, and has been leading the way in our state to help combat Zika; and

WHEREAS, Southern Research engineers are developing technologies to help the Department of Defense, NASA, the intelligence community, and commercial companies solve some of the most challenging problems in the fields of mechanics, materials, and systems development, including work on Prompt Global Strike and an aerial imaging system utilized by NASA to capture full motion high definition video of rocket launches from greater than 25 miles away; and

WHEREAS, the men and women of its energy and environment division continue to be focused on producing cleaner energy, providing clean water, developing new sources of energy, including energy storage, and driving innovation that enhances and promotes our state in a multitude of ways such as the Southeastern Solar Research Center and Gen IV Nuclear research; and

WHEREAS, Southern Research continues to do its part to help with job and industry recruitment in Alabama through not only its own successes, but in partnership with a number of economic development entities throughout the state; now therefore,

BE IT RESOLVED BY THE LEGISLATURE OF ALABAMA, BOTH HOUSES THEREOF CONCURRING, That it is a privilege to commend the significant achievements and meritorious efforts of Southern Research, and by copy of this resolution, we extend our congratulations on 75 years of accomplishment and best wishes for another 75 years of scientific and engineering excellence.

President and Presiding Officer of the Senate

Speaker of the House of Representatives

SJR13
Senate 18-AUG-16
I hereby certify that the within Senate Joint Resolution originated in and was adopted by the Senate.

Patrick Harris
Secretary

House of Representatives
Adopted: 19-AUG-16

By: Senator Smitherman